End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,79,900 KRW | -1.96% | -6.06% | -10.72% |
24/05 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
10/05 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.72% | 2.71TCr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+45.66% | 4.07TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr | |
-8.12% | 1.12TCr |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Celltrion Provides Earnings Guidance for the Year 2017